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Natural killer (NK) cells were so named for their uniqueness in killing certain tumor and virus-
infected cells without prior sensitization. Their functions are modulated in vivo by several
soluble immune mediators; interleukin-15 (IL-15) being the most potent among them in
enabling NK cell homeostasis, maturation, and activation. During microbial infections, NK
cells stimulated with IL-15 display enhanced cytokine responses. This priming effect has
previously been shown with respect to increased IFN-γ production in NK cells upon IL-
12 and IL-15/IL-2 co-stimulation. In this study, we explored if this effect of IL-15 priming
can be extended to various other cytokines and observed enhanced NK cell responses to
stimulation with IL-4, IL-21, IFN-α, and IL-2 in addition to IL-12. Notably, we also observed
elevated IFN-γ production in primed NK cells upon stimulation through the Ly49H acti-
vation receptor. Currently, the fundamental processes required for priming and whether
these signaling pathways work collaboratively or independently for NK cell functions are
poorly understood. To identify the key signaling events for NK cell priming, we examined
IL-15 effects on NK cells in which the pathways emanating from IL-15 receptor activation
were blocked with specific inhibitors. Our results demonstrate that the PI3K–AKT–mTOR
pathway is critical for cytokine responses in IL-15 primed NK cells. Furthermore, this path-
way is also implicated in a broad range of IL-15-induced NK cell effector functions such
as proliferation and cytotoxicity. Likewise, NK cells from mice treated with rapamycin to
block the mTOR pathway displayed defects in proliferation, and IFN-γ and granzyme B pro-
ductions resulting in elevated viral burdens upon murine cytomegalovirus infection. Taken
together, our data demonstrate the requirement of PI3K–mTOR pathway for enhanced NK
cell functions by IL-15, thereby coupling the metabolic sensor mTOR to NK cell anti-viral
responses.
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INTRODUCTION
Natural killer cells are innate immune lymphocytes that were so
named for their propensity to kill target cells without the need
for antigenic stimulation (1). They are equipped with several
inhibitory receptors that bind to certain surface molecules like self-
major histocompatibility complex (MHC) class I thereby avoiding
destruction of healthy cells. Known as “missing self” hypothe-
sis, NK cells can directly lyse target cells with reductions in or
deficiency of MHC class I molecules (2). In addition, signals
through activating receptors stimulate NK cells to release pre-
existing cytotoxic granules such as perforin and granzymes thereby
destroying infected and cancerous cells. Simultaneously, the sig-
nals also induce production of inflammatory cytokines such as
IFN-γ and TNF-α (3). NK cell effector responses are often deter-
mined by the integration of signal transductions pathways from
multiple activating and inhibitory receptors (4, 5). Even though
NK cells were originally recognized as “ready to act” cells that
can immediately cope with virus-infected or transformed cells (6,
7), NK cells derived from laboratory strains of mice housed in
specific pathogen-free (SPF) environment show minimal effector
functions (8–10). Unlike human NK cells, naïve mouse NK cells
are devoid of perforin and granzyme B cytotoxic granules and
require additional stimulations to induce rapid translation of their
pre-existing mRNAs in order to be fully equipped for action (9).
Several cytokines have been identified to provide such addi-
tional stimulations, interleukin-15 (IL-15) being most potent
among them in inducing NK cell homeostasis, survival, and mat-
uration. Studies have shown that IL-15−/− mice exhibit selective
loss of memory phenotype CD8+ T cells, NKT cells, and NK cells
(11–13). IL-15R is a heterotrimeric receptor consisting of a unique
α chain, a shared β subunit with IL-2, and a common γ subunit
with several cytokines (12). A pivotal role of dendritic cell (DC)-
expressed IL-15 receptor α chain (IL-15Rα) for trans-presenting
IL-15 to NK cells has been demonstrated (14, 15). During inflam-
mation, NK cells are recruited to lymph nodes where they are
activated by trans-presentation of IL-15 by IL-15Rα expressed
on DCs (8). Engagement of IL-15R on NK cells causes auto-
phosphorylation and activation of Janus kinases (JAK1 and JAK3),
which induces at least three parallel signaling cascades: Ras–Raf–
MEK, PI3K–AKT–mTOR, and signal transduction and activation
of transcription (STAT) 5 pathways (12, 16). Data from Stat5
knock-out and NK cell-specific Stat5 knock-out mice showed that
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NK cells are absent in peripheral lymphoid organs, suggesting a
critical importance of the IL-15–STAT5 pathway in NK cell devel-
opment (17–19). In addition, similar to STAT5 knock-out mice, a
severe reduction in NK cell numbers has been found in a patient
containing the STAT5b mutation (20). Studies have shown that
IL-15 activates NK cells to become equipped with cytotoxic gran-
ules and sensitize them to secondary stimuli. This “priming” has
been previously demonstrated with respect to IL-12 and IL-15 co-
stimulation, which induces an exaggerated IFN-γ response in NK
cells (8, 21, 22). However, it is largely unknown if one of three
major signaling pathways is responsible for NK cell priming or it
is achieved by a collaborative effort of multiple pathways.
In this study, we set out to investigate the signaling pathway
downstream of IL-15 stimulation responsible for sensitizing NK
cells to subsequent stimulations. We hypothesized that IL-15-
mediated priming of NK cells is not restricted to IL-12 stimulation,
but can be extended to other cytokines. Our data indicated that
prior exposure to IL-15 dramatically increased NK cell responses
to stimulations though Ly49H activation receptor in addition to
a myriad of cytokine receptors that employ the JAK–STAT path-
way. Furthermore, we show that PI3K–mTOR pathway is crucial
for major effector functions in addition to the IL-15-mediated
priming process for cytokine responses in NK cells. To translate
the importance of PI3K–mTOR pathway for NK cell functions
in vivo, we treated mice with rapamycin to block mTOR kinase
activity downstream of PI3K (23, 24). Interestingly, we observed
attenuated anti-viral responses by NK cells upon challenge with
murine cytomegalovirus (MCMV) in rapamycin-treated mice.
Taken together, our results demonstrate that the PI3K–AKT–
mTOR pathway is central to IL-15-induced activation of vital NK
cell functions.
MATERIALS AND METHODS
MICE, MCMV INFECTION, AND IN VIVO RAPAMYCIN TREATMENTS
WT C57BL/6 and B6.SJL (C57BL/6 congenic mice with CD45.1
allotype marker) mice from Charles River were housed in SPF
environment and used for experiments at 7–12 weeks of age. All
procedures were approved by and conducted in accordance with
the institution’s animal guidelines of the University of Ottawa.
Smith strain MCMV stocks were generated in our laboratory from
infected salivary glands of BALB/c mice and viral titers determined
by standard plaque assays. WT C57BL/6 mice were infected with
5,000 plaque forming unit (PFU) of MCMV intraperitoneally
4 h after first rapamycin injection. Rapamycin (3 mg/kg/day) or
DMSO as vesicle control was administered through intraperitoneal
injections once per day until sacrificed.
REAGENTS AND ANTIBODIES
The following monoclonal antibodies were used: α-CD16/32
(clone 2.4G2) from Bioexpress, α-human/mouse Granzyme B
(clone GB12) and fixable far red live/dead from Invitrogen. α-
Ly49H (clone 3D10), α-TCR-β (clone H57-597), α-NK1.1 (clone
PK136), α-CD49b (clone DX5), α-CD8a (clone 53-6.7), and α-
IFN-γ (clone XMG1.2) from eBiosciences, α-BrdU (clone B44),
α-CD4 (clone RM4-5), and mouse isotype IgG-κ from BD Bio-
sciences. For detection of phosphorylated signals, BD PhosFlow
antibodies against pSTAT1 (clone 49), pSTAT3 (clone 4), pSTAT4
(clone 38), pSTAT5 (clone 47), and pSTAT6 (clone 18) were used
except α-pS6 ribosomal protein (Ser235/236) (clone D57.2.2E)
from Cell Signaling. Cytokines, recombinant murine (rm) IL-2,
rmIL-4, rmIL-12, rmIL-15/IL-15Rα complex, and rmIL-21, are
from eBiosciences except rmIFN-α from Miltenyi Biotec. To phys-
iologically mimic trans-presentation of IL-15 to NK cells by DCs
ex vivo, we decided to use rmIL-15/IL-15R complex to enable
IL-15 stimulation of NK cells. The rmIL-15/IL-15R complex
concentration of 10 ng/ml was determined to induce maximum
response in NK cells without inducing equivalent stimulation on
CD8 T cells. The following inhibitors were purchased from Cal-
biochem and used at the indicated concentrations; JAK inhibitor
I (0.4µM), STAT5 inhibitor III pimozide (10µM), PI3K inhibitor
LY294002 (4µM), mTOR inhibitor rapamycin (1.6µM in vitro;
3 mg/kg in vivo),AKT inhibitor VIII AKTi-1/2 (0.8µM), and MEK
inhibitor PD98059 (20µM).
CELL ISOLATION AND STIMULATION
Spleens were harvested under sterile conditions, and single cell
suspension of splenic leukocytes was generated after red blood cell
lysis and filtration through 70µm nylon mesh. Cells were cultured
in RP-10 media (RPMI-1640 from HyClone, 10% FCS, 10 mM
HEPES, 1× penicillin/streptomycin, 1% l-Glutamine, 50µM β-
mercaptoethanol) at 37°C and 5% CO2. To block signaling mole-
cules, 1× 106 splenic leukocytes were incubated in 96-well plates
(2× 107/ml in 150µl) in triplicates with the inhibitors for 1 h
prior to stimulation with rmIL-15/IL-15Rα complex (10 ng/ml).
For evaluation of STAT activation, cells were harvested 24 h later,
washed, and rested for 4 h in RP-10 media (without IL-15) to
remove the reversible cell-permeable inhibitors and the residual
effects of IL-15 on STAT activation. This was followed by stim-
ulation with rmIL-21 (100 ng/ml), rmIL-12 (10 ng/ml), rmIFN-
α (1,000 U/ml), rmIL-4 (100 ng/ml), or rmIL-2 (50 ng/ml) for
30 min before harvesting for flow analyses. The working con-
centrations of the cytokines were determined to induce maximal
responses in NK cells.
FLOW CYTOMETRY
For detection of phosphorylated STATs (pSTATs) and S6 riboso-
mal protein, cells were blocked with 2.4G2 and surface stained for
NK and T cells with monoclonal antibodies specific for NK1.1
and TCR-β. Following fixation with BD Cytofix/Cytoperm buffer
and permeabilization with pre-chilled 100% methanol, cells were
stained for respective intracellular pSTATs or pS6, as previously
reported (25). Alternatively, cells were surface stained for NK and
T cell proportions followed by staining for intracellular Granzyme
B expression immediately after 24 h of IL-15 stimulation. Simi-
larly, cells were recovered after 24 h of IL-15 treatment and surface
stained for NK and T cells along with the live/dead viability marker
to measure the extent of cell toxicity after inhibitor treatment. NK
cell proliferation was measured at 42 h (ex vivo) post treatment
with 10, 50, or 100 ng/ml of IL-15/IL-15Rα complex or 2.5 days
(in vivo) post-MCMV infection. BrdU (200µM) was added to
cultures (ex vivo) or given as i.p. injections (in vivo) 2 h prior
to intracellular staining for BrdU incorporation with anti-BrdU
antibody (26).
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To measure IFN-γ production, IL-15/IL-15Rα complex-treated
cells were added to 96-well plates with plate bound α-Ly49H or
control IgG antibody (both 10µg/ml). Alternatively, IL-15/IL-
15Rα complex-treated cells were added to 96-well plates with
either media alone or rmIL-12 (50 ng/ml). Cells were stimulated
for 5 h, last 4 h in the presence of 5µg/ml brefeldin A, harvested
and stained for intracellular IFN-γ expression. For intracellu-
lar IFN-γ measurements in vivo, splenic leukocytes were har-
vested post-infection at D1.5 and incubated in media containing
brefeldin A in addition to DMSO or rapamycin (1.6µM) for 4 h,
followed by staining for intracellular IFN-γ. In all conditions,
freshly isolated untreated naïve total splenic leukocytes were used
as controls. All intracellular procedures were carried out using
BD Cytofix/Cytoperm protocols. Cells were suspended in staining
buffer (1× PBS, 2%FCS, and 0.09% sodium azide), acquired using
FACS Cyan ADP and analyzed with Kaluza software v2 (Beckman
Coulter).
PLAQUE AND CYTOKINE QUANTIFICATION ASSAYS
For measuring viral burdens in organs, spleens and livers from
infected mice were homogenized by Magna lyser (Roche Applied
Science) and the lysates were appropriately diluted and overlaid
on mouse embryonic fibroblasts cells in duplicates in 10% Dul-
becco Modified Eagle’s Medium (DMEM) (DMEM from HyClone,
10% FCS, 10 mM HEPES, 1× penicillin/streptomycin, 1% l-
Glutamine). Plaques were counted 3 days later and represented as
log PFU/organ. Blood serum and lysates of homogenized spleen
and livers from mice were appropriately diluted and analyzed for
the production of mouse IFN-γ using Cytometric Bead Array
kit (BD Biosciences). Samples were prepared according to man-
ufacturer’s instructions, acquired on FACS Cyan ADP (Beckman
Coulter) and analyzed using the BD FCAP Array Software (BD
Biosciences).
NK CELL CYTOTOXICITY ASSAY
Natural killer cell cytotoxicity was measured by analyzing the
anti-tumor activity of NK cells against YAC-1 target cells. Splenic
leukocytes were isolated from infected and control mice treated
with either DMSO or rapamycin. Spleen populations were sur-
face stained for NK and T cells to identify NK cell proportions
and was adjusted to ensure that equal numbers of NK cells were
used in assays at the indicated effector cell (NK cell) to target
ratio. Each adjusted sample was prepared in sterile NK media
(RPMI-1640 from HyClone, 10% FCS, 10 mM HEPES, 1× peni-
cillin/streptomycin, 1% l-Glutamine, 50µM β-mercaptoethanol,
1% non-essential amino acids, 1 mM sodium pyruvate) contain-
ing either DMSO or 1.6µM rapamycin. YAC-1 cells were cul-
tured in sterile RP-10 media and labeled with 100µCi of 51Cr
for 1 h at 37°C, washed three times with PBS, and made to a
concentration of 5× 104 cells/ml in NK medium. In V-bottom
96-well plates, 100µl of YAC-1 cells were added in triplicates
and incubated for 4 h with 100µl of effector cells with NK
cell: target ratios ranging from 0.3:1 to 10:1. Supernatants were
then used to quantify the amount of 51Cr released due to spe-
cific lysis of YAC-1 targets by NK cells, and counted using 2470
WIZARD2 Automatic Gamma Counter (Perkin Elmer). NK cyto-
toxicity was calculated according to the formula: % specific 51Cr
release= [(experimental release−minimum release)/(maximum
release−minimum release)]× 100.
RNA EXTRACTION AND QUANTITATIVE PCR
Total RNA was extracted from splenic leukocytes using TRI-
ZOL reagent (GIBCO BRL) according to manufacturer’s instruc-
tions. cDNA was reverse transcribed from 500 ng of total RNA
in a 20-µl reaction using first strand cDNA synthesis kit
(Thermo Scientific). For quantification of β-actin and IL-15
genes by real-time PCR, one-tenth volume of cDNA was added
to a 15-µl reaction of FastStart Universal Probe Master Kit
(Roche) and amplified using ViiA 7 Dx real-time PCR Instru-
ment (Applied Biosystems). Expression of IL-15 in all the sam-
ples was normalized to β-actin levels. The primer sequences
for β-actin are forward: 5′CCAACCGTGAAAAGATGAC3′
and reverse: 5′GTACGACCAGAGGCATACAG3′, for IL-15
are forward: 5′ACATCCATCTCGTGCTACTTGT3′ and reverse:
5′GCCTCTGTTTTAGGGAGACCT3′ (27).
STATISTICS
Significance of results was determined by two-tailed unpaired
student t tests (*p≤ 0.05; **p≤ 0.01; ***p≤ 0.001) and graphed
using Graph Pad Prism 5 software.
RESULTS
IL-15 PRIMES NK CELLS THROUGH A MYRIAD OF CYTOKINE
RECEPTORS AND Ly49H ACTIVATION RECEPTOR
In addition to inhibitory and activating receptors, NK cells express
receptors for various cytokines. Because the priming effect has
only been shown with respect to enhanced responsiveness to IL-
12 when co-stimulated with IL-2 or IL-15 (8, 21, 22, 28–30), we
hypothesized that IL-15 “priming” of NK cell responses can be
extended to a broader range of cytokines that transmit their signal
by employing the JAK–STAT pathway. Signal transduction follow-
ing cytokine stimulation involves multiple pathways, making it dif-
ficult to determine whether functional consequences result from
direct or indirect effects. Therefore, to measure direct responses to
cytokine stimulation, we decided to evaluate the level of pSTATs,
an activation event occurring proximal to cytokine receptors.
IFN-γ production in NK cells is regulated by IL-12 in a STAT4-
dependent manner (31, 32). Therefore, we first set out to analyze
the sequential responses to IL-12 stimulation (rather than co-
stimulation) in NK cells that have been previously exposed to
IL-15. Indeed, our data indicate that NK cells pre-stimulated
with IL-15 display enhanced phosphorylation of STAT4 and con-
sequently increased IFN-γ production upon IL-12 stimulation
compared to naïve cells (Figures 1A,B). To test whether IL-15
can prime NK cells for an extensive list of cytokines in addition
to IL-12, we have stimulated naïve and IL-15/IL-15Rα complex-
primed splenic leukocytes with five representative cytokines (i.e.,
Type I IFN, IL-21, IL-12, IL-2, and IL-4), which transmit their sig-
nals through STAT1, STAT3, STAT4, STAT5, and STAT6 molecules
respectively (33). Notably, our results demonstrated that in addi-
tion to previously described IL-12 effect, IL-15 can prime NK cells
to stimulations with all cytokines tested based on enhanced pSTAT
expression (Figure 1C). It is worth noting that this priming effect
was predominantly observed in NK cells compared to T cells.
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FIGURE 1 | Interleukin-15 primes NK cells through a broad range of
cytokine receptors and the Ly49H activation receptor. NK cells were
defined as NK1.1+TCRβ− populations and T cells as NK1.1-TCRβ+
populations. (A) Naïve and IL-15 primed splenic leukocytes (for 24 h) were
stimulated with IL-12 for 30 min followed by intracellular staining for
phosphorylated STAT4 protein. Histograms depict the expression of
phosphorylated STAT4 protein in NK and T cells. Naïve cells are depicted
in blue, IL-15-treated cells in red, and isotype antibody (negative controls
for intracellular staining) in gray. (B) Naïve and IL-15 primed splenic
leukocytes were stimulated with media or IL-12 for 5 h; brefeldin A was
added during the last 4 h. Cells were then stained for intracellular IFN-γ.
Histograms depict IFN-γ expression upon IL-12 stimulation in NK cells and
summarized in graphs where each bar indicates an average of duplicate
samples. (C) Naïve and IL-15 primed splenic leukocytes (for 24 h) were
stimulated with the indicated cytokines. After 30 min, cells were stained
for intracellular expression of phosphorylated STAT proteins. Histograms
depict the phosphorylation of respective STAT proteins in NK and T cells.
(D) Naïve and IL-15 primed splenic leukocytes were stimulated on
α-Ly49H or control antibody coated plates for 5 h; brefeldin A was added
during the last 4 h. Cells were then stained for intracellular IFN-γ.
Histograms depict IFN-γ expression upon Ly49H or control IgG1
stimulation in NK1.1+TCRβ− cells and summarized in graphs where each
bar indicates an average of duplicate samples. Figures are representative
of three independent experiments. Numbers on histograms indicate
proportions of IFN-γ-expressing cells. Significance of results was
determined between naïve and primed cells. **p ≤0.01; ***p≤0.001.
We next analyzed whether this increased responsiveness in
primed NK cells can be extended to stimulation through activation
receptors. It is known that stimulation through both IL-12–STAT4
and Ly49H–Syk/ZAP70 receptors induces IFN-γ production in
NK cells (3–5). We therefore analyzed the IFN-γ expression in
primed NK cells after stimulation through Ly49H activation recep-
tor. Our results indicate that primed NK cells display significantly
elevated IFN-γ expression in NK cells when stimulated though
their Ly49H receptor compared to naïve cells (Figure 1D). Even
though stimulations induced basal IFN-γ production in naïve
NK cells, IL-15-primed NK cells produced dramatically enhanced
level of IFN-γ. Taken together, IL-15-priming sensitizes NK cells
to stimulations through cytokine receptors and Ly49H activation
receptor.
REQUIREMENT OF PI3K–mTOR PATHWAY IN PRIMED NK CELL
RESPONSES TO CYTOKINE STIMULATION
IL-15 binding to its receptor initiates signaling through activa-
tion of JAK 1/3, which induce at least three parallel cascades:
Ras–Raf–MEK, PI3K–AKT–mTOR, and STAT5 (12, 16). In order
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to identify which signaling pathway downstream of IL-15–JAK
activation is predominately responsible for NK cell priming, we
prepared NK cells in which each pathway is abrogated by pretreat-
ment with specific cell-permeable inhibitors. We used PD98059
for blocking ERK 1/2, LY294002 for blocking PI3K, and pimozide
(STAT5 inhibitor III) for blocking STAT5. In addition, AKT-1/2
inhibitor (CAS 612847-09-3) and rapamycin (mTOR inhibitor)
were used to investigate the signaling events downstream of PI3K
pathway.
To optimize the conditions for each inhibitor at which IL-
15 priming can be achieved without compromising cell via-
bility, we analyzed toxicity in NK cells within a few hours of
inhibitor treatment. Notably, we observed that NK cell deaths
in samples with working concentrations of inhibitors were com-
parable to controls (without any inhibitor treatment), suggest-
ing no direct toxicity contributed by inhibitors (Figure 2A). In
addition, NK cells were also measured for cell death after 24 h
of IL-15 stimulation. Cells were treated with inhibitors for 1 h
followed by IL-15/IL-15Rα complex treatment. Since IL-15 is
essential for NK cell survival, cells deprived of IL-15 exhibit
FIGURE 2 | Effect of various inhibitors on NK cell viability. (A) Naïve
splenic leukocytes were incubated with indicated concentrations of JAK
and STAT5 inhibitors for 1, 3, and 5 h, in addition to media alone or working
concentrations of the other inhibitors for 5 h. Toxicity of the inhibitors was
analyzed by staining for proportions of live/dead cells among various
populations. Graph depicts percentages of NK cells that stain positive for
dead staining. (B) Similarly, splenic leukocytes were incubated with working
concentrations of the inhibitors (see Materials and Methods) or DMSO
controls for 1 h, following which cells were cultured for 24 h in media with
or without IL-15/IL-15Rα. Graph depicts percentages of IL-15-treated NK cells
that stain positive for dead staining. NK cells were defined as NK1.1+TCRβ−
populations. Figures are representative of at least three independent
experiments. Each bar indicates an average of duplicate samples.
drastic cell deaths (Figure 2B). JAK1/3–STAT5 has been known
for mediating pro-survival effects of IL-15 in the cell (12, 34,
35). As expected, blocking JAK and STAT5 pathway resulted
in dramatic cell deaths similar to NK cells deprived of IL-15.
Notably, all other inhibitors tested maintained NK cell viability
compared to IL-15-treated controls (cells without any inhibitor
treatment), suggesting that blocking of PI3K and MEK pathways
at the indicated inhibitor concentrations do not affect NK cell
survival.
Having established the optimal concentration of inhibitors, we
investigated the major pathway responsible for cytokine respon-
siveness of IL-15 primed NK cells. IL-15-induced pathways were
blocked in naïve splenic leukocytes by adding inhibitors 1 h before
IL-15/IL-15α complex stimulation for a total of 24 h. Treated cells
were washed and rested for 4 h to remove residual effects of IL-
15 and inhibitors. They were then evaluated for phosphorylated
STAT3 and STAT4 upon the stimulation with IL-12 and IL-21,
respectively. Blocking of either JAK or STAT5 abrogated pSTAT
expression, however it can be attributed to negative effect of
those inhibitors on NK cell survival. Notably, treatment with PI3K
inhibitor abrogated the priming effect, with pSTAT levels similar
to that of naïve cells. Such inhibition was also observed with block-
ing mTOR and AKT, downstream signaling components of PI3K
pathway, suggesting that PI3K–AKT–mTOR pathway is critical for
optimal responses of “primed” NK cells to cytokine stimulations
(Figures 3A,B). Treatment of naïve cells with the inhibitors did not
show any reduction in their cytokine responsiveness compared to
controls (data not shown), indicating that the pathway is specif-
ically implicated in IL-15 primed NK cells. In addition, blocking
MEK reduced pSTAT levels significantly with IL-21 and modestly
with IL-12 stimulations. Therefore, IL-15 treatment enhances NK
cell responsiveness to IL-12 and IL-21 stimulations and the effects
of priming is abrogated by blocking PI3K–AKT–mTOR pathway
during IL-15 treatment.
PI3K–mTOR PATHWAY IS IMPLICATED IN IL-15-INDUCED EFFECTOR
FUNCTIONS OF NK CELLS
During inflammation, NK cells are exposed to IL-15 at early
stages in lymph nodes and become activated and recruited
to sites of inflammation in the periphery (8) where they can
produce pro-inflammatory cytokines like IFN-γ and kill tar-
get cells via perforin/granzyme-mediated cytotoxicity. Therefore,
we decided to evaluate whether the PI3K–AKT–mTOR path-
way is also required for NK cell effector functions induced by
IL-15. Consistent with previous data, IL-15 primed NK cells
produced significantly more IFN-γ than naïve cells upon IL-
12 and α-Ly49H stimulation. Interestingly, IFN-γ production in
both stimulations was severely reduced by PI3K–AKT–mTOR
inhibition (Figures 4A,B). Blocking of JAK abrogated IFN-γ
production, however as observed previously (Figure 2B), this
could be due to the negative effect of JAK inhibitor on NK cell
survival after 24 h of incubation. Blocking STAT5 reduced IFN-
γ production upon IL-12 stimulation of NK cells, but STAT5
inhibitor only moderately affected IFN-γ production in NK
cells with α-Ly49H stimulation. This suggests that unlike in
IL-12 stimulation, blocking STAT5 may not be detrimental for
primed NK cell responses to α-Ly49H stimulation. In addition,
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FIGURE 3 | PI3K–AKT–mTOR pathway is critical for responsiveness of
primed NK cells to cytokine stimulation. Splenic leukocytes were
incubated with working concentrations of the inhibitors for 1 h; followed by
culturing of cells for 24 h with IL-15/IL-15Rα. Naïve and inhibitor
treated-primed splenic leukocytes were washed and rested for 4 h followed
by stimulation with the indicated cytokines. After 30 min of cytokine
stimulation, cells were stained for intracellular phosphorylated STAT
proteins. Histograms depict expression of phosphorylated STAT3 and
STAT4 proteins in primed NK cells upon stimulation with IL-21 (A) and IL-12
(B) respectively and the effect of various inhibitors on the same. Results are
summarized in graphs where each bar indicates an average of triplicate
samples. Figures are representative of at least three independent
experiments. Numbers on histograms indicate percentages of pSTAT
expression in cells. NK cells were defined as NK1.1+TCRβ− populations.
Significance of results was determined with IL-15 primed cells without any
inhibitor treatment. *p≤0.05; ***p≤0.001.
MEK inhibition in NK cells reduced IL-15-induced elevation in
IFN-γ production with both cytokine and activation receptor
stimulation.
Unlike human NK cells, NK cells from mouse housed in SPF
vivarium are devoid of perforin/granzyme B expression, but can
translate the cytotoxic granules from pre-existing mRNA pools
upon the activation by IL-15 (9). Consistently, IL-15-treated cells,
but not naïve NK cells, expressed significantly more granzyme
B (Figure 5A). Blocking PI3K–AKT–mTOR pathway drastically
reduced granzyme B expression in IL-15 activated NK cells. Inter-
estingly, MEK did not affect the ability of primed NK cells to
express granzyme B.
FIGURE 4 | PI3K–AKT–mTOR pathway is required for optimal IFN-γ
production in primed NK cells. Splenic leukocytes were incubated with
working concentrations of the inhibitors for 1 h; followed by culturing of
cells for 24 h with IL-15/IL-15Rα. Naïve and inhibitor treated-primed splenic
leukocytes were stimulated with IL-12 or in α-Ly49H coated plates for 5 h;
Brefeldin A was added in the last 4 h. Cells were then stained for
intracellular expression of IFN-γ. Histograms depict IFN-γ expression in NK
cells upon stimulation with IL-12 (A) and plate-bound α-Ly49H (B)
respectively and the effect of various inhibitors on IFN-γ expression. Results
are summarized in graphs where each bar indicates an average of duplicate
samples. Figures are representative of two independent experiments.
Numbers on histograms indicate proportions of IFN-γ-expressing NK cells.
NK cells were defined as NK1.1+TCRβ− populations. Significance of results
on each bar was determined with primed cells without any inhibitor
treatment. *p≤0.05; **p≤0.01; ***p≤0.001.
Since we identified that the PI3K–mTOR pathway is impli-
cated in NK cell effector functions, we next investigated the effect
of this pathway in proliferation of NK cells. Splenic leukocytes
were stimulated with three different concentrations (10, 50, and
100 ng/ml) of IL-15/IL-15Rα complex and pulsed with BrdU 2 h
prior to analysis for BrdU incorporation at 42 h. Consistent with
their negative effect on survival, blocking either JAK or STAT5
completely abrogated NK cell proliferation (Figure 5B). Notably,
NK cell proliferation was severely affected in PI3K–AKT–mTOR
inhibition and this was reproducible in NK cells treated with higher
doses of IL-15/IL-15Rα complex. When the effect of MEK inhi-
bition was analyzed at different IL-15 doses, blocking MEK did
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FIGURE 5 | PI3K–AKT–mTOR pathway is required for granzyme B
production and proliferation of IL-15-treated NK cells. (A) Splenic
leukocytes were incubated with working concentrations of the inhibitors for
1 h; followed by culturing of cells for 24 h with IL-15/IL-15Rα. Naïve and primed
cells were stained for intracellular granzyme B. Histograms depict intracellular
granzyme B expression in NK cells and the effect of inhibitors on the
expression. Results are summarized in graphs where each bar indicates an
average of triplicate samples. (B) Splenic leukocytes were incubated with
working concentrations of the inhibitors for 1 h; followed by culturing of cells
for 24 h with IL-15/IL-15Rα at the indicated concentrations. BrdU was added
in vitro (one-tenth volume of a 96-well) to the cells, 2 h prior to intracellular
staining for BrdU. Histograms depict BrdU incorporation in naïve and primed
NK cells and the effect of inhibitors on NK cell proliferation at different
concentrations of IL-15/IL-15Rα. Results are summarized in graphs where each
bar indicates an average of six samples pooled from two independent
experiments. Figures are representative of at least three independent
experiments. Numbers on histograms indicate proportions of cells expressing
granzyme B or percentages of BrdU incorporation in NK cells. NK cells were
defined as NK1.1+TCRβ− populations. Significance of results on each bar was
determined with primed cells without any inhibitor treatment. ***p≤0.001.
not abrogate NK cell proliferation with 10 and 100 ng/ml of IL-
15/IL-15Rα complex. However, there was decrease in proliferation
in NK cells primed with 50 ng/ml of IL-15/IL-15Rα complex, but
this was not as dramatic as the effects seen with inhibition of
the PI3K–AKT–mTOR pathway. Taken together, our data suggest
that PI3K–AKT–mTOR pathway is central for IL-15-mediated NK
cell effector responses including granzyme B expression, prolif-
eration, and IFN-γ production. MEK is important for cytokine
responses and IFN-γ production but is not critical for granzyme
B expression and proliferation; suggesting differential regulation
of MEK upon IL-15 stimulation for effector functions of NK
cells.
REQUIREMENT OF mTOR IN MCMV-INDUCED NK CELL EFFECTOR
FUNCTIONS
To further extend our findings to NK cell functions in vivo, we
decided to evaluate the effects of blocking mTOR pathway by
administering rapamycin during MCMV infection, where critical
role of NK cell for early control of virus replication is well known
(3, 5). WT B6 mice were given mTOR inhibitor rapamycin or
DMSO by intraperitoneal injections daily and either infected with
5,000 PFU MCMV or left uninfected as controls. To confirm inhi-
bition of the mTOR pathway by rapamycin treatment in vivo, we
evaluated levels of phosphorylated S6 ribosomal protein which is
a target of S6 kinase downstream of mTOR pathway (24). Signif-
icantly low phosphorylation levels of S6 ribosomal protein were
found in rapamycin-treated mice compared to controls, indicating
efficient blocking of mTOR pathway by rapamycin (Figure 6A).
Next, we evaluated the effects of rapamycin treatment on IL-15
production. IL-15 not only plays a key role in survival, and prolif-
eration, but also functions as a central mediator of inflammation
by amplifying the inflammatory response in various immune cells
(12). To confirm if rapamycin treatment does not hamper IL-15
production thereby enabling NK cell priming in vivo,we quantified
IL-15 mRNA levels in splenic leukocytes on day 1.5 by real-time
PCR. IL-15 was induced upon MCMV infection and no significant
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FIGURE 6 | In vivo inhibition of mTOR affects NK cell cytotoxic
responses. Rapamycin- or DMSO-treated mice were either uninfected or
given 5,000 PFU MCMV i.p. and sacrificed on day 1.5. Splenic leukocytes
were isolated and used for the following analyses: (A) Graph depicts
intracellular expression of phosphorylated S6 ribosomal protein in splenic NK
cells. (B)Total RNA was extracted and quantified for IL-15 production by
real-time PCR. Graph depicts IL-15 mRNA expression in controls and infected
samples normalized to β-actin levels. Graphs depict percentages of
intracellular granzyme B (C) and IFN-γ (D) expressions in NK cells. Infected
and control organs were isolated, homogenized, and the lysates used for
analysis of cytokine production along with blood serum by cytometric bead
assays. Graphs depict the amount of IFN-γ levels in serum (E), spleens (F),
and livers (G). Data are representative of n=5–7 mice pooled from two
independent experiments that were matched for sex and age of mice. (H)To
measure NK cytotoxic activity, infected and control splenic leukocytes were
incubated ex vivo with their target YAC-1 tumor cells at the indicated effector
(NK cells): target cell ratios for 4 h in media containing DMSO or rapamycin.
Graph shows percentages of YAC-1 cells lysed by splenic NK cells where each
point indicates an average of triplicate samples. NK cells were defined as
NK1.1+TCRβ− populations. Figures are representative of at least three
independent experiments. Significance of results was determined between
DMSO and rapamycin-treated samples. **p≤0.01; ***p≤0.001.
differences in expression levels between rapamycin-treated and
control samples were observed (Figure 6B).
We then set out to evaluate effector functions of NK cells dur-
ing MCMV infections such as intracellular IFN-γ and granzyme B
production in rapamycin-treated mice on day 1.5. Both granzyme
B (Figure 6C) and IFN-γ (Figure 6D) expression levels were
induced after MCMV infection in NK cells. However, their pro-
ductions were diminished in rapamycin-treated mice compared
to controls. At this time point, MCMV infection induced a
well-defined innate cytokine peak response of IFN-γ in serum,
which was dramatically reduced (>75%), indicating that cytokine
response of NK cells is compromised in the rapamycin-treated
mice (Figure 6E). We observed similar patterns in the organs,
rapamycin-treated mice displayed reduced IFN-γ production in
the infected spleens (Figure 6F) and livers (Figure 6G). Addition-
ally, we analyzed NK cell cytotoxic responses ex vivo by measuring
the ability of NK cells from rapamycin and DMSO-treated con-
trol and infected mice to kill the NK cell-sensitive YAC-1 cells.
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FIGURE 7 | In vivo inhibition of mTOR affects NK cell proliferative and
anti-viral responses. Rapamycin or DMSO-treated mice were either
uninfected or given 5,000 PFU MCMV i.p. and sacrificed on day 2.5
post-infection for the following analyses: (A) Splenic leukocytes were
isolated from infected and control organs and analyzed for the effects of
rapamycin treatment on mTOR pathway. Graph depicts intracellular
expression of phosphorylated S6 ribosomal protein in NK cells. (B) BrdU
was injected intraperitoneally (2 h prior to sacrifice) following which splenic
leukocytes were isolated from infected and control organs and analyzed for
NK cell proliferation. Graph depicts proportion of BrdU incorporation in NK
cells. (C) Infected and control organs were isolated, homogenized, and the
lysates used for viral quantification by plaque assays. Graph indicates viral
titers in the infected spleens and livers of DMSO or rapamycin-treated
mice. Data are representative of n=4–7 mice pooled from two
independent experiments that were matched for sex and age of mice. NK
cells were defined as NK1.1+TCRβ− populations. For a given organ showing
undetectable plaque, the titer of virus for that organ was arbitrarily set to
the limit of detection for statistical calculation and graph representation.
Figures are representative of at least three independent experiments.
Significance of results was determined between DMSO and
rapamycin-treated samples. *p≤0.05; **p≤0.01; ***p≤0.001.
NK cells from infected mice were able to efficiently lyse target cells
while naïve cells displayed poor killing activity. Notably, splenic NK
cells from rapamycin-treated MCMV-infected mice on day 1.5 had
attenuated lytic activities toward target tumor cells (Figure 6H).
As previously mentioned, NK cell anti-viral defenses are critical
at early stages for the control of MCMV replication. Therefore, we
decided to investigate the consequences of blocking mTOR path-
way in NK cells by treating mice with rapamycin and evaluated
NK cell responses to MCMV infections on day 2.5. Significant
reductions in the phosphorylation of S6 ribosomal protein were
observed in MCMV-infected rapamycin-treated mice compared
to controls, indicating efficient blocking of the mTOR pathway
(Figure 7A). The proportions of NK cells were comparable to con-
trols and unaffected by rapamycin treatment (data not shown).
However consistent with our ex vivo data, proliferation of NK
cells as measured by BrdU incorporation was severely affected
in rapamycin-treated mice during infections (Figure 7B). Conse-
quently, when virus loads in organs of mice treated with rapamycin
was measured at this time point, significantly higher viral burdens
were found in spleens and livers compared to those that received
DMSO (Figure 7C). Taken together, blocking mTOR pathway
in vivo affects cytokine production, and proliferative and cyto-
toxic responses of NK cells during infections, thereby resulting in
elevated viral burdens.
DISCUSSION
In this report, we have demonstrated that prior exposure to IL-15
primes NK cell responses to further stimulations through a myr-
iad of cytokine receptors and the Ly49H activation receptor. By
using specific cell-permeable reversible inhibitors to enable effi-
cient blocking of individual signaling pathways emanating from
IL-15 receptor, we further demonstrated that PI3K–mTOR path-
way is critical for IL-15-induced major NK cell functions like
granzyme B expression, IFN-γ production and proliferation. In
addition, our data showed that in vivo blocking of mTOR by
rapamycin affects NK cell cytotoxic and proliferative responses
during MCMV infection, resulting in elevated viral burdens. Taken
together, our results show that the PI3K–mTOR pathway is indis-
pensable for efficient NK cell activity and provides an example of
how mTOR activity is linked to immune functions of NK cells.
The serine/threonine kinase mTOR is a well-studied regula-
tor of cell growth and metabolism. It acts downstream of the
PI3K–AKT pathway and is activated by growth factors, nutri-
ents, and various other signals (23, 36). Activation of mTOR
complex 1 (mTORC1) leads to the phosphorylation of several
downstream targets such as 70-S6 kinase (S6K); and this kinase
activity of mTORC1 is blocked by rapamycin treatment (24).
Recently, accumulated evidence demonstrates that mTOR pathway
can regulate functions of immune cells by modulating metab-
olism of the individual immune cells. For example, rapamycin
inhibits T cell proliferation and therefore is used as immuno-
suppressive agent for the prevention of allograft rejection (37).
However, treating rapamycin at low doses improves naïve CD8
T cell differentiation to memory CD8 T cells in vivo, suggesting
immunomodulatory roles in memory response (24). In addition,
mTOR-deficient CD4 T cells fail to differentiate into Th1, Th2, and
Th17 cells and this defect was largely due to impaired phospho-
rylation of respective STAT molecules required for each lineage
differentiation. This is similar to our ex vivo experiments where
diminished levels of pSTATs in primed NK cells was observed with
rapamycin treatment (38). Here, we show the dramatic effects of
rapamycin treatment in NK cells during virus infection. To our
knowledge, this is the first study to link the IL-15-induced mTOR
pathway to NK cell functions in vivo during acute virus infections.
The effect of rapamycin on NK cell functions during MCMV
infection was dramatic, showing severe defects in IFN-γ and
granzyme B productions in addition to proliferation. It is well
known that granzymes and IFN-γ are required for efficient NK
cell anti-viral activity (39–42). Consequently, mTOR inhibition
affected NK cell cytotoxic responses toward target tumor YAC-1
cells and resulted in elevated viral loads in the infected organs.
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Presumably, the drastic effect of rapamycin on NK cells is due to
the fact that they are the most metabolically active cell popula-
tion during acute MCMV infection. During infections, NK cells
undergo rapid blastogenesis and this expansion is dependent on
IL-15 (32, 43). Our data suggest that mTOR pathway might be
required for the efficient metabolic transformation of NK cells
and the associated immune functions.
PI3K–mTOR pathway is implicated in IFN-γ production by
primed NK cells when stimulated through both IL-12 and Ly49H
receptors. We analyzed responses of primed NK cells to Ly49H acti-
vation receptor, as Ly49H recognition of the viral ligand m157 dur-
ing MCMV infection triggers NK cell proliferation and enhances
anti-viral responses (44–46). However, Ly49H expression in B6
mice strains is restricted to roughly 50% of NK cells; therefore fur-
ther investigation of NK cell priming to other NK cell activation
receptors is warranted. Moreover, several receptors on NK and T
cells using different adaptor molecules such as CD3, Syk/ZAP70,
DAP10, DAP12, etc. could be employed upstream and possibly
converge to a common PI3K–mTOR pathway for NK cell effector
functions (47–49).
Previous studies have shown that MEK inhibition affected NK
cytotoxic activity by interfering with the mobilization of cyto-
toxic granules toward target cells in human NK cell lines, while
proliferation of NK cells was unaffected (50). This was further
shown to be regulated upstream by Syk/ZAP70 molecules asso-
ciated with the NK activation receptors, that in turn leads to the
phosphorylation of PI3K and to the activation of downstream
Rac1–PAK1–MEK–ERK molecules (51, 52). The importance of
the MEK pathway in NK cell cytokine responses was also reported
by another group which demonstrated that the production of pro-
inflammatory cytokines like IFN-γ, IL-6, and TNF-αwere reduced
by MEK blockade in human peripheral blood NK cells. Simi-
larly, MEK was regulated upstream by the activation of Syk–PI3K
pathway upon CD160 receptor ligation on NK cells (53). Both
these studies are consistent with our data that implicate MEK in
responsiveness to IL-12 and IL-21 stimulations and IFN-γ pro-
duction upon IL-12 and α-Ly49H stimulations, but is not critical
for proliferation. Our data show that the intracellular production
of granzyme B was unaffected with MEK inhibition, but this does
not necessarily translate to efficient NK cytotoxic responses. NK
cell activity is regulated at multiple steps and therefore to fur-
ther understand the effect of MEK inhibition on NK cell lytic
activity, the mobilization of cytotoxic granules toward the tar-
get cells needs to be analyzed in our model. On the other hand,
both in vivo and ex vivo results clearly show that PI3K–AKT–
mTOR is required for granzyme B and IFN-γ productions in NK
cells.
We have demonstrated that the signaling axis of IL-15–PI3K–
mTOR in NK cells is important for their cellular proliferation,
responsiveness to cytokine stimulations, and cytotoxic functions.
IL-2/IL-15 share receptor subunits of IL-2/IL-15R-β and -γ chains
and both are being widely used for ex vivo expansion of NK cells in
immunotherapy. Their promising therapeutic capacity for a vari-
ety of human malignancies has stimulated an interest in using NK
cells for anti-cancer treatments (54, 55). Therefore, understanding
the molecular mechanisms by which IL-15 primes and activates
NK cells will allow manipulation of IL-15 signaling for improving
NK cell-based therapeutic strategies against cancers and infectious
diseases.
AUTHOR CONTRIBUTIONS
Neethi Nandagopal performed majority of the experiments, ana-
lyzed the data, and wrote the manuscript. Alaa Kassim Ali
performed the NK killing assay and generated Figure 6H while
Amandeep Kaur Komal was involved in designing and performing
cytokine detection assays. Seung-Hwan Lee designed the study,
supervised the experiments, and wrote the manuscript.
ACKNOWLEDGMENTS
This research was supported by funding from J. P. Bickell Founda-
tion and Canadian Institutes of Health Research to Seung-Hwan
Lee. Seung-Hwan Lee holds a Canada Research Chair in Viral
Infection and Immunity.
REFERENCES
1. Kiessling R, Petranyi G, Karre K, Jondal M, Tracey D, Wigzell H. Killer
cells: a functional comparison between natural, immune T-cell and antibody-
dependent in vitro systems. J Exp Med (1976) 143(4):772–80. doi:10.1084/jem.
143.4.772
2. Ljunggren HG, Karre K. In search of the ‘missing self ’: MHC molecules and
NK cell recognition. Immunol Today (1990) 11(7):237–44. doi:10.1016/0167-
5699(90)90097-S
3. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer
cells in antiviral defense: function and regulation by innate cytokines. Annu Rev
Immunol (1999) 17:189. doi:10.1146/annurev.immunol.17.1.189
4. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat
Immunol (2008) 9(5):495–502. doi:10.1038/ni1581
5. Lee SH, Miyagi T, Biron CA. Keeping NK cells in highly regulated antiviral
warfare. Trends Immunol (2007) 28(6):252–9. doi:10.1016/j.it.2007.04.001
6. Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cyto-
toxic cells with specificity for mouse Moloney leukemia cells. Specificity
and distribution according to genotype. Eur J Immunol (1975) 5(2):112–7.
doi:10.1002/eji.1830050208
7. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse
lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of
reactivity and specificity. Int J Cancer (1975) 16(2):216–29. doi:10.1002/ijc.
2910160205
8. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells
prime natural killer cells by trans-presenting interleukin 15. Immunity (2007)
26(4):503–17. doi:10.1016/j.immuni.2007.03.006
9. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, et al. Acqui-
sition of murine NK cell cytotoxicity requires the translation of a pre-existing
pool of granzyme B and perforin mRNAs. Immunity (2007) 26(6):798–811.
doi:10.1016/j.immuni.2007.04.010
10. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on
resting NK cells for the activation of natural cytotoxicity and cytokine secretion.
Blood (2006) 107(1):159–66. doi:10.1182/blood-2005-04-1351
11. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al.
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin
15-deficient mice. J Exp Med (2000) 191(5):771–80. doi:10.1084/jem.191.5.771
12. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lym-
phoid homeostasis. Annu Rev Immunol (2006) 24:657–79. doi:10.1146/annurev.
immunol.24.021605.090727
13. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human
disease. Blood (2001) 97(1):14–32. doi:10.1182/blood.V97.1.14
14. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine
dendritic cells require IL-15R alpha to prime NK cells. J Immunol (2004)
173(6):3594–8. doi:10.4049/jimmunol.173.6.3594
15. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and
presents IL-15 in trans to neighboring cells. Immunity (2002) 17(5):537–47.
doi:10.1016/S1074-7613(02)00429-6
16. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical
roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21,
Frontiers in Immunology | Molecular Innate Immunity April 2014 | Volume 5 | Article 187 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nandagopal et al. IL-15–PI3K–mTOR pathway in NK cell functions
and their signaling pathways. Immunol Rev (2004) 202:67–83. doi:10.1111/j.
0105-2896.2004.00203.x
17. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A
novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival
and development. Blood (2011) 117(5):1565–73. doi:10.1182/blood-2010-06-
291633
18. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. Stat5 is
required for IL-2-induced cell cycle progression of peripheral T cells. Immunity
(1999) 10(2):249–59. doi:10.1016/S1074-7613(00)80025-4
19. Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB,
Davey HW, et al. Stat5b is essential for natural killer cell-mediated prolifera-
tion and cytolytic activity. J Exp Med (1998) 188(11):2067–74. doi:10.1084/jem.
188.11.2067
20. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, et al. Charac-
terization of immunodeficiency in a patient with growth hormone insensitivity
secondary to a novel STAT5b gene mutation. Pediatrics (2006) 118(5):e1584–92.
doi:10.1542/peds.2005-2882
21. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper
MA, et al. Differential cytokine and chemokine gene expression by human
NK cells following activation with IL-18 or IL-15 in combination with IL-
12: implications for the innate immune response. J Immunol (1999) 162(8):
4511–20.
22. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al.
Interleukin (IL) 15 is a novel cytokine that activates human natural killer
cells via components of the IL-2 receptor. J Exp Med (1994) 180(4):1395–403.
doi:10.1084/jem.180.4.1395
23. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell
(2012) 149(2):274–93. doi:10.1016/j.cell.2012.03.017
24. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation
initiation and cancer. Oncogene (2006) 25(48):6416–22. doi:10.1038/sj.onc.
1209888
25. Miyagi T, Lee SH, Biron CA. Intracellular staining for analysis of the expres-
sion and phosphorylation of signal transducers and activators of transcription
(STATs) in NK cells. Methods Mol Biol (2010) 612:159–75. doi:10.1007/978-1-
60761-362-6_11
26. Lee SH, Fragoso MF, Biron CA. Cutting edge: a novel mechanism bridging innate
and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2
receptors on NK cells. J Immunol (2012) 189(6):2712–6. doi:10.4049/jimmunol.
1201528
27. Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, et al. Mutual
repression between steroid and xenobiotic receptor and NF-kappaB signaling
pathways links xenobiotic metabolism and inflammation. J Clin Invest (2006)
116(8):2280–9. doi:10.1172/JCI26283
28. Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Cytokine production and
killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination
of IL-12 and IL-18. J Immunol (2000) 165(4):1847–53. doi:10.4049/jimmunol.
165.4.1847
29. Grant LR, Yao ZJ, Hedrich CM, Wang F, Moorthy A, Wilson K, et al. Stat4-
dependent, T-bet-independent regulation of IL-10 in NK cells. Genes Immun
(2008) 9(4):316–27. doi:10.1038/gene.2008.20
30. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer
cells to interleukin-12 through up-regulation of the interleukin-12 receptor and
STAT4. Blood (2000) 95(10):3183–90.
31. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and
enhanced development of Th2 cells in Stat4-deficient mice. Nature (1996)
382(6587):174–7. doi:10.1038/382174a0
32. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY,
et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regu-
lation of NK cell responses to viral infection. J Immunol (2002) 169(8):4279–87.
doi:10.4049/jimmunol.169.8.4279
33. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev
Immunol (1998) 16:293–322. doi:10.1146/annurev.immunol.16.1.293
34. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, et al. Develop-
mental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity (1995)
3(6):771–82. doi:10.1016/1074-7613(95)90066-7
35. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, et al. Stat5a/b are
essential for normal lymphoid development and differentiation. Proc Natl Acad
Sci U S A (2006) 103(4):1000–5. doi:10.1073/pnas.0507350103
36. Xu X,Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. Semin
Immunol (2012) 24(6):429–35. doi:10.1016/j.smim.2012.12.005
37. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J
Med (2004) 351(26):2715–29. doi:10.1056/NEJMra033540
38. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T
cell differentiation, function, and metabolism. Immunity (2010) 33(3):301–11.
doi:10.1016/j.immuni.2010.09.002
39. Loh J, Chu DT, O’Guin AK, Yokoyama WM, Virgin HW. Natural killer cells uti-
lize both perforin and gamma interferon to regulate murine cytomegalovirus
infection in the spleen and liver. J Virol (2005) 79(1):661–7. doi:10.1128/JVI.79.
1.661-667.2005
40. Orange JS, Wang B, Terhorst C, Biron CA. Requirement for natural killer
cell-produced interferon gamma in defense against murine cytomegalovirus
infection and enhancement of this defense pathway by interleukin 12 adminis-
tration. J Exp Med (1995) 182(4):1045–56. doi:10.1084/jem.182.4.1045
41. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control
of murine cytomegalovirus infection by natural killer cells. J Virol (1997)
71(1):267–75.
42. van Dommelen SL, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, Degli-
Esposti MA. Perforin and granzymes have distinct roles in defensive immunity
and immunopathology. Immunity (2006) 25(5):835–48. doi:10.1016/j.immuni.
2006.09.010
43. Orange JS, Biron CA. Characterization of early IL-12, IFN-alphabeta, and TNF
effects on antiviral state and NK cell responses during murine cytomegalovirus
infection. J Immunol (1996) 156(12):4746–56.
44. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of
cytomegalovirus by activating and inhibitory NK cell receptors. Science (2002)
296(5571):1323–6. doi:10.1126/science.1070884
45. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV, et al. Recog-
nition of a virus-encoded ligand by a natural killer cell activation receptor. Proc
Natl Acad Sci U S A (2002) 99(13):8826–31. doi:10.1073/pnas.092258599
46. Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. Specific
and nonspecific NK cell activation during virus infection. Nat Immunol (2001)
2(10):951–6. doi:10.1038/ni714
47. Djeu JY, Jiang K, Wei S. A view to a kill: signals triggering cytotoxicity. Clin
Cancer Res (2002) 8(3):636–40.
48. Deshpande P, Cavanagh MM, Le Saux S, Singh K, Weyand CM, Goronzy JJ. IL-7-
and IL-15-mediated TCR sensitization enables T cell responses to self-antigens.
J Immunol (2013) 190(4):1416–23. doi:10.4049/jimmunol.1201620
49. Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the
interleukin 15 receptor signaling pathway. Nat Immunol (2007) 8(12):1345–52.
doi:10.1038/ni1524
50. Wei S, Gamero AM, Liu JH, Daulton AA, Valkov NI, Trapani JA, et al. Con-
trol of lytic function by mitogen-activated protein kinase/extracellular regu-
latory kinase 2 (ERK2) in a human natural killer cell line: identification of
perforin and granzyme B mobilization by functional ERK2. J Exp Med (1998)
187(11):1753–65. doi:10.1084/jem.187.11.1753
51. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, et al. Pivotal
role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer
cells. Nat Immunol (2000) 1(5):419–25. doi:10.1038/80859
52. Jiang K, Zhong B, Gilvary DL, Corliss BC, Vivier E, Hong-Geller E, et al. Syk reg-
ulation of phosphoinositide 3-kinase-dependent NK cell function. J Immunol
(2002) 168(7):3155–64. doi:10.4049/jimmunol.168.7.3155
53. Rabot M, El Costa H, Polgar B, Marie-Cardine A, Aguerre-Girr M, Barakonyi A,
et al. CD160-activating NK cell effector functions depend on the phosphatidyli-
nositol 3-kinase recruitment. Int Immunol (2007) 19(4):401–9. doi:10.1093/
intimm/dxm005
54. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer
cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 12(4):239–52.
doi:10.1038/nri3174
55. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, et al. Natural
killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther
(2005) 5(10):1303–15. doi:10.1517/14712598.5.10.1303
Conflict of Interest Statement: The Guest Associate Editor Andrew P. Makrigian-
nis declares that, despite being affiliated to the same institution as authors Neethi
Nandagopal, Alaa Kassim Ali, Amandeep Kaur Komal and Seung-Hwan Lee, the
review process was handled objectively and no conflict of interest exists. The authors
www.frontiersin.org April 2014 | Volume 5 | Article 187 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nandagopal et al. IL-15–PI3K–mTOR pathway in NK cell functions
declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest.
Received: 16 January 2014; paper pending published: 10 February 2014; accepted: 08
April 2014; published online: 23 April 2014.
Citation: Nandagopal N, Ali AK, Komal AK and Lee S-H (2014) The critical role of
IL-15–PI3K–mTOR pathway in natural killer cell effector functions. Front. Immunol.
5:187. doi: 10.3389/fimmu.2014.00187
This article was submitted to Molecular Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2014 Nandagopal, Ali, Komal and Lee. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Molecular Innate Immunity April 2014 | Volume 5 | Article 187 | 12
